Claims for Patent: 9,150,649

Summary for Patent: 9,150,649

Title:	Potent conjugates and hydrophilic linkers
Abstract:	Linkers for binding drugs to cell binding agents are modified to hydrophilic linkers by incorporating a polyethylene glycol spacer. The potency or the efficacy of the cell-binding agent-drug conjugates is surprisingly enhanced several folds in a variety of cancer cell types, including those expressing a low number of antigens on the cell surface or cancer cells that are resistant to treatment. A method for preparing maytansinoids bearing a thioether moiety and a reactive group which allows the maytansinoid to be linked to a cell-binding agent in essentially a single step is also provided.
Inventor(s):	Singh; Rajeeva (Framingham, MA), Kovtun; Yelena (Stow, MA), Wilhelm; Sharon D. (Brookline, MA), Chari; Ravi V. J. (Newton, MA)
Assignee:	ImmunoGen, Inc. (Waltham, MA)
Application Number:	12/574,466
Patent Claims:	1. A compound represented by a formula selected from the following: ##STR00003## ##STR00004## wherein n is an integer from 1 to 2000; R is H and q is 1, or R is CH.sub.3 and q is 2. 2. A conjugate represented by a formula selected from: ##STR00005## ##STR00006## wherein mAb is a monoclonal antibody; n is an integer from 1 to 2000; m is an integer from 2 to 15; R is H and q is 1 or R is CH.sub.3 and q is 2, wherein the monoclonal antibody binds to an antigen selected from the group consisting of: EpCAM, CA6, CD2, CD3, CD4, CD5, CD6, CD11, CD11a, CD18, CD19, CD20, CD22, CD26, CD30, CD33, CD37, CD38, CD40, CD44, CD56, CD70, CD79, CD105, CD138, EphA receptor, EphB receptor, epidermal growth factor receptor (EGFR), EGFRvIII, HER2, HER3, insulin-like growth factor I receptor (IGF-IR), CanAg, MUC1, MUC16, vascular endothelial growth factor (VEGF), tissue factor (TF), mesotheliri, cripto, Apo2, alpha.sub.vbeta.sub.3 integrin, alpha.sub.vbeta.sub.5 integrin, alpha.sub.vbeta.sub.6 integrin, and folate receptor. 3. The compound of claim 1, wherein the compound is represented by the following formula: ##STR00007## 4. The conjugate of claim 2, wherein the conjugate is represented by the following formula: ##STR00008## 5. The compound of claim 1, wherein n is 1 to 14. 6. The compound of claim 1, wherein n is 1 to 4. 7. The conjugate of claim 2, wherein n is 1 to 14. 8. The conjugate of claim 2, wherein n is 1 to 4. 9. The compound of claim 3, wherein n is 1 to 14. 10. The compound of claim 3, wherein n is 1 to 4. 11. The conjugate of claim 4, wherein n is 1 to 14. 12. The conjugate of claim 4, wherein n is 1 to 4. 13. A composition comprising any one of the conjugates of claim 2, a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable carrier, diluent or excipient. 14. The composition of claim 13, wherein n is 1 to 14. 15. The composition of claim 13, wherein n is 1 to 4. 16. The conjugate of claim 2, wherein the monoclonal antibody is a resurfaced monoclonal antibody or an antigen-binding fragment thereof, or a resurfaced single chain monoclonal antibody or an antigen-binding fragment thereof. 17. The conjugate of claim 2, wherein the monoclonal antibody is a humanized monoclonal antibody or an antigen-binding fragment thereof, or a humanized single chain monoclonal antibody or an antigen-binding fragment thereof. 18. The conjugate of claim 2, wherein the monoclonal antibody is a chimeric antibody or an antigen-binding fragment thereof, a domain antibody, or an antigen-binding fragment thereof. 19. The conjugate of claim 2, wherein the monoclonal antibody is MY9 antibody that binds to CD33, anti-B4 antibody that binds to CD19, C242 antibody that binds to CanAg, or a monoclonal antibody that binds to an antigen selected from the group consisting of EpCAM, CD2, CD3, CD4, CD5, CD6, CD11, CD19, CD20, CD22, CD26, CD30, CD33, CD37, CD38, CD40, CD44, CD56, CD79, CD105, CD138, EphA receptor, EphB receptor, EGFR, EGFRvIII, HER2, HER3, mesothelin, cripto, alpha.sub.vbeta.sub.3 integrin, alpha.sub.vbeta.sub.5 integrin, and alpha.sub.vbeta.sub.6 integrin. 20. The conjugate of claim 2, wherein the monoclonal antibody is selected from the group consisting of: My9-6 antibody that binds to CD33, or a humanized monoclonal antibody, a human monoclonal antibody, or a resurfaced monoclonal antibody thereof; anti-B4 antibody that binds to CD19, or a humanized monoclonal antibody, a human monoclonal antibody, or a resurfaced monoclonal antibody thereof; C242 antibody that binds to CanAg, a humanized monoclonal antibody, a human monoclonal antibody, or a resurfaced monoclonal antibody thereof; N901 antibody that binds to CD56, or a humanized monoclonal antibody, a human monoclonal antibody, or a resurfaced monoclonal antibody thereof; DS6 antibody that binds to CA6, or a humanized monoclonal antibody, a human monoclonal antibody, or a resurfaced monoclonal antibody thereof; CNTO 95 antibody that binds to alpha.sub.vbeta.sub.3, alpha.sub.vbeta.sub.5 or alpha.sub.vbeta.sub.6 integrin, or a humanized monoclonal antibody, a human monoclonal antibody, or a resurfaced monoclonal antibody thereof; B-B4 antibody that binds to CD138, or a humanized monoclonal antibody, a human monoclonal antibody, or a resurfaced monoclonal antibody thereof, trastuzumab, pertuzumab, bivatuzumab, rituximab, and a monoclonal antibody that binds to EphA2 receptor, CD38 or IGF-IR.

Details for Patent 9,150,649

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997		2028-04-30
Idec Pharmaceuticals Corp.	RITUXAN	rituximab	Injection	103737	02/19/2002		2028-04-30
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998		2028-04-30
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017		2028-04-30
Genentech, Inc.	PERJETA	pertuzumab	Injection	125409	06/08/2012		2028-04-30